Novavax focuses on variant-specific vaccines in expanded deal with South Korean manufacturer

20 Jul 2022
endpts.com
VaccineEmergency Use Authorization
The rollercoaster ride for Novavax’s Covid-19 vaccine has finally resulted in an emergency use authorization from the FDA. However, as the Omicron variant spreads, the company is turning to a Korean manufacturer to upgrade its capabilities. The Maryland-based company inked agreements with SK bioscience for the manufacturing and supply of a version of its vaccine that’s specifically designed to protect against Omicron, Novavax announced on Tuesday. SK also committed to manufacturing Novavax’s vaccine in prefilled syringes, though the financial details were not disclosed. The agreement builds on an existing deal that Novavax and SK struck back in 2021, according to the Korean news site T he Korea Herald. SK already manufactures drugs substance for the current vaccine, but soon that will also cover a wide range of Covid-19 variants, including the Omicron BA.5 variant now dominant in the US, Novavax said. “We are accelerating our clinical program evaluating an Omicron BA.5 component to our vaccine and look forward to continuing to work with SK bioscience as an important manufacturing partner,” Novavax CEO Stanley Erck said. The Korea Herald reported that the companies’ deal for the supply of prefilled syringes is worth $29.8 million. “SK bioscience will begin work to enable the manufacturing process for commercial supply of the vaccine in prefilled syringes in 2023,” Novavax said in a statement. SK has the exclusive commercialization rights for the vaccine in South Korea, and the partners have joint rights in both Vietnam and Thailand. Novavax finally got over the FDA hurdle last week, following months of delays . The company is set to release its first lot in the US soon, according to a report from Reuters. SK has recently been looking to the US for more business. In January the company took a stake in the Pennsylvania-based Center for Breakthrough Medicines, investing $350 million of equity financing.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.